Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has announced that the FDA has approved Symbicort 160/4.5mcg for the twice daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Subscribe to our email newsletter
The FDA approval is based on results from two pivotal clinical trials, Shine (six-month) and Sun (12-month), which found Symbicort significantly improved lung function within five minutes of the first dose and sustained that lung function improvement for the duration of the studies.
Howard Hutchinson, chief medical officer of AstraZeneca, said: “With the approval of Symbicort in chronic obstructive pulmonary disease (COPD), patients have a new treatment option that can deliver lung function improvement and daily symptom control, together with a rapid onset of action.”